Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Heli Vajavaara; Frida Ekeblad; Harald Holte; Judit Jorgensen; Suvi-Katri Leivonen; Mattias Berglund; Peter Kamper; Holger J Moller; Francesco D'Amore; Daniel Molin; Gunilla Enblad; Maja Ludvigsen; Ingrid Glimelius; Sirpa Leppa

doi:10.3324/haematol.2020.278182

Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Haematologica. 2021 Sep 1;106(9):2502-2506. doi: 10.3324/haematol.2020.278182.

Authors

Affiliations

¹ Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
² Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
³ Department of Oncology and KG Jebsen center for B-cell malignancies, Oslo University Hospital, Oslo.
⁴ Department of Hematology, Aarhus University Hospital, Aarhus.
⁵ Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus.
⁶ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus.
⁷ Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Medicine, division of clinical epidemiology, Karolinska Institutet, Solna. Ingrid.glimelius@igp.uu.se.
⁸ Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki. sirpa.leppa@helsinki.fi.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD*
Antigens, Differentiation, Myelomonocytic
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Prognosis
Receptors, Cell Surface

Substances

Antigens, CD
Antigens, Differentiation, Myelomonocytic
CD163 antigen
Receptors, Cell Surface

Grants and funding

Funding: the study was supported by grants from the Academy of Finland (to SL), Finnish Cancer Foundation (to SL), Juselius Foundation (to SL), Ida Montin Foundation (to HV), Finnish Society for Oncology (to HV), University of Helsinki (to SL), Helsinki University Hospital (to SL), Swedish Cancer Society (19 0123 Pj 01 H and 19 0109 SCIA) (to IG), Swedish Society of Medicine (to IG) and Lions Research Cancer Fund, Uppsala Sweden (to IG).